Results 111 to 120 of about 149,571 (273)
Al-Mustansiriyah Journal of Pharmaceutical Sciences, 2018 The aim of this work was to promote an intranasal mucoadhesive drug allocation system to simplify the systemic delivery of ondansetron HCL (OND-HCl) for the immediate and sustain prevention of repeated nausea and vomiting caused by the initial and ...
Nidhal K. Maraie, Yasser Qasim Almajidi
doaj +1 more source
Dosing Interval Extension of Dupilumab in CRSwNP: Five‐Year Real World Outcomes
International Forum of Allergy &Rhinology, EarlyView.ABSTRACT Background Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent, often Type 2‐mediated inflammatory disease that markedly impairs quality of life. While dupilumab provides rapid improvement, there is limited evidence on long‐term outcomes beyond 2 years, and the clinical impact of dosing‐interval extension remains unclear.
Nicholas J. Campion +15 more
wiley +1 more source
Uncovering Cystic Fibrosis Carrier: Insights From a Heterozygous CFTR‐F508del Rabbit Model
International Forum of Allergy &Rhinology, EarlyView.ABSTRACT Background Chronic rhinosinusitis (CRS) is a heterogeneous inflammatory disorder frequently associated with impaired mucociliary clearance and bacterial infection. Individuals carrying a single cystic fibrosis transmembrane conductance regulator (CFTR) mutation exhibit partial CFTR dysfunction and are increasingly recognized as being at risk ...
Do‐Yeon Cho +9 more
wiley +1 more source
International Forum of Allergy &Rhinology, EarlyView.ABSTRACT Background To determine the safety and efficacy of laser ablation of the posterior nasal nerve (PNN) for the treatment of chronic rhinitis. Methods This study was a single‐center, prospective, single‐blinded, randomized sham‐controlled trial. Patients with a 24‐h reflective Total Nasal Symptom Score (rTNSS) ≧ 5, rhinorrhea ≧ 2, and congestion ≧
Jyun‐Yi Liao +9 more
wiley +1 more source
Therapeutics and Clinical Risk Management, 2018 AH Kibbe,1 TS Franko,2 VM Shah2 1Department of Pharmaceutical Sciences, Nesbitt School of Pharmacy, Wilkes University, Wilkes-Barre, PA, USA; 2Department of Clinical Pharmacy, Nesbitt School of Pharmacy, Wilkes University, Wilkes-Barre, PA, USA ...
Kibbe AH, Franko TS, Shah VM
doaj
International Forum of Allergy &Rhinology, EarlyView.ABSTRACT Introduction Chronic rhinosinusitis (CRS) is an inflammatory disease with many different contributing factors, including bacterial infection. CRS patients are typically managed with medical therapies; however, these treatments frequently fail, leaving surgery as the only viable option.
Sintayehu Ambachew +8 more
wiley +1 more source
Extent of Sinus Surgery Is Associated With Disease Control in Biologic Treated Type 2 Dominant CRS
International Forum of Allergy &Rhinology, EarlyView.ABSTRACT Background A greater benefit of biologics is observed after surgery in Type 2 chronic rhinosinusitis with nasal polyps (CRSwNP). However, the extent of surgery remains undefined in many studies. This study evaluated the extent of surgery on disease control in patients receiving biologics for refractory Type 2 dominant CRSwNP.
Nicholas J. Campion +11 more
wiley +1 more source
Frontiers in AllergyChronic Rhinosinusitis with Nasal Polyps (CRSwNP) is a chronic inflammatory disease. Its severe uncontrolled form may share, with asthma and atopic dermatitis, the pathophysiological mechanism of T helper 2 inflammation, characterized by tissue ...
F. Anastasi +8 more
doaj +1 more source
International Forum of Allergy &Rhinology, EarlyView.ABSTRACT Background Olfactory dysfunction is a hallmark feature of COVID‐19, yet the potential for recovery with long‐standing COVID‐19‐related smell loss (CRSL) remains uncertain, particularly when treatment is initiated years later. This study evaluated olfactory outcomes in patients with CRSL compared with non‐COVID‐19‐related smell loss (non‐CRSL),
John W. Hunsicker +6 more
wiley +1 more source